KRAS and neoplasm: Another insight which can be extracted from our analysis is related to FDA approved ADC target NECTIN4, which was upregulated in 4 tumor type gene mutation combinations including OV/TP53, THCA/BRAF, PAAD/KRAS, PAAD/SMAD4, and was downregulated in 25 tumor type gene mutation combination.